№ lp_1_2_24619
File format: docx Character count: 23326 File size: 184 KB
This document outlines the Patient Group Direction for the use of zanamivir in the treatment of seasonal influenza within healthcare settings in the UK, specifying authorised practitioners and organisational responsibilities.
Year: 2025
Region / City: UK
Topic: Seasonal Influenza Treatment
Document Type: Patient Group Direction
Organization: UK Health Security Agency (UKHSA)
Author: Shilan Ghafoor, Dr. Matthew Donati, Lesley McFarlane
Target Audience: Healthcare practitioners, care facility staff
Validity Period: 08 August 2025 to 07 August 2028
Approval Date: 08 August 2025
Amendment Date: 08 August 2025
Expiry Date: 07 August 2028
Review Date: 08 August 2027
Version: 05.0
Changes: Expanded inclusion criteria, updated medical and pregnancy information, added neuropsychiatric side effects
Development: UK Health Security Agency (UKHSA)
Note: Contextual description
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Information for people with lung disease on high dose inhaled steroids
Note: Year
Topic: Lung disease, steroid treatment
Document type: Information sheet
Organization / institution: Sheffield Teaching Hospitals NHS Foundation Trust
Author: Respiratory and endocrinology teams
Target audience: People with lung disease on high dose inhaled steroids
Increasing the lung dose of inhaled suspensions – Comparison between microsuspension and nanosuspension formulations delivered by a breath-actuated mesh nebuliser
Year: 2026
Region / city: Taipei City, Helsinki, Malmö
Topic: Pharmaceutical formulation, Inhalation therapy
Document type: Research article
Institution: HCmed Innovations Co. Ltd., Nanoform Finland Oyj, Inhaled Delivery Consulting AB
Author: Edgar H. Cuevas Brun, Barry Derham, Yulia Degtyareva, Pablo Luis Gutierrez Carvalho, Gunilla Petersson, Sarah Byrne, Lucy Hardaker, Jesse Heikkilä, Elisabetta Micelotta
Target audience: Researchers, pharmaceutical professionals, healthcare practitioners
Period of validity: N/A
Date of approval: N/A
Date of changes: N/A
Administration of Inhaled Medications
Note: Year
Context: Instructional document detailing the process for administering inhaled medications to pets with asthma using an inhaler and a spacing chamber.
Topics: zanamivir Relenza inhaled